Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

Summary

This is a single-center, open-label, randomized crossover study being conducted in three cohorts of healthy adult subjects. Approximately 36 subjects will be randomized to one of three cohorts (approximately 12 subjects per cohort) and they will receive both a single dose of E2006 in capsule formulation and a single dose of E2006 in tablet formulation, in random sequence, at a 1:1 ratio. The doses to be tested will be 2.5 mg, 10 mg, and 25 mg.

Timeline

Start

2012-08

Primary completion

2012-10

Completion

2012-12

Drugs

Indications